Answers are grounded in this paper and cite their sources.
Cervical and vaginal epithelial hyperplasia and hyperkeratosis were observed in a 6-month repeat-dose toxicology study in rats administered the long-acting relaxin agonist (LY), with mammary fibroadenomas noted following a 6-month off-dose period. Two investigative studies characterized these findings: a 6-month study in intact and ovariectomized (OVX) rats with interim sacrifices at 1, 3, and 6 months, and a 12-month study in intact rats. In the 6-month study, no test article-related effects occurred in OVX rats, demonstrating dependence on an intact ovarian hormonal milieu. In intact rats, cervicovaginal hyperplasia/hyperkeratosis and stromal edema with or without cervical/vaginal prolapse progressed in incidence and severity as animals entered reproductive senescence, then plateaued with no progression to neoplasia. No effect on estrous cyclicity was observed. In the 12-month study, LY increased the incidence of mammary fibroadenomas and diffuse pituitary hyperplasia. These findings were attributed to an interaction between sustained relaxin pharmacology and age-related changes in endogenous hormones during progression through reproductive senescence. Rodent reproductive senescence differs fundamentally from human menopause, and this spectrum of hormonally dependent findings is likely rodent-specific but warrants consideration in clinical risk assessment in the context of human hormonal milieu and age.
No takes yet. Share an insight, caveat, or question.
Bhaskaran et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: